Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 5/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134355 | 0.90 | PRMT6 (0.49) | PRMT6SYKPSMB5KEAP1KDM4E | |
| SCHEMBL4640294 | 0.81 | KEAP1 (0.56) | PRMT6KEAP1KDM4EHPGD | |
| SCHEMBL8903063 | 0.81 | TDP1 (0.56) | SYKCYP4F2CYP4A11TDP1 | |
| SCHEMBL4425984 | 0.80 | CYP4F2 (0.64) | SYKCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL10242910 | 0.80 | PRMT6 (0.53) | PRMT6PSMB5KEAP1KDM4EPOLB | |
| SCHEMBL12302785 | 0.79 | PRMT6 (0.59) | PRMT6PSMB5KEAP1KDM4EPOLB | |
| SCHEMBL30540945 | 0.79 | FFAR1 (0.55) | SYKCYP4F2CYP4A11TDP1 | |
| SCHEMBL21476713 | 0.79 | FFAR1 (0.64) | SYKCYP4F2CYP4A11 | |
| SCHEMBL10243163 | 0.79 | PRMT6 (0.59) | PRMT6PSMB5KEAP1KDM4EPOLB | |
| SCHEMBL14018792 | 0.78 | SMN1; SMN2 (0.55) | SYKCYP4F2CYP4A11KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | ASTEX THERAPEUTICS LTD. (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | ASTEX THERAPEUTICS LTD. (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | ASTEX THERAPEUTICS LTD. (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1951681-A1 | NOVEL 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007058581-A1 | NOVEL 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058581-A1 | NOVEL 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | PRMT6 553/4885SYK 2396/4885PSMB5 187/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | PRMT6 1140/4885SYK 2804/4885PSMB5 520/4885 |
| US-20080255167-A1 | Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use | PSEN2, PSEN1, MAPT | PRMT6 103/4885SYK 3893/4885PSMB5 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.